Expres2ion Biotechnologies announces positive results for its breast cancer vaccine

Copenhagen, December 2021 “ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion”) announces that its capsid virus-like particle (cVLP) breast cancer vaccine candidate ES2B-C001 demonstrated strong tumor-growth inhibiting effect in a mice model, thus reaching an important pre-clinical milestone ahead of schedule.” Read more about the exciting news HERE. Expres2ion was Gemstone Capital’s first IPO…